Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1031

Sort by

Sort Order Select

Journal Articles

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Dai Chihara, Graça M. Dores, Christopher R. Flowers, Lindsay M. Morton

Blood (2021) 138 (9): 785–789.

https://doi.org/10.1182/blood.2020010497

Published: 2021

Includes: Supplemental data

Journal Articles

The rise of a new “great teacher”

Amanda B. McBride, Pierluigi Porcu

Blood (2021) 138 (3): 205–206.

https://doi.org/10.1182/blood.2021011754

Published: 2021

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes for PTCL: which pathway to success?

Julie M. Vose

Blood (2021) 137 (19): 2570–2571.

https://doi.org/10.1182/blood.2020009850

Published: 2021

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia

Tomas Jelinek, Jana Zuchnicka

Blood (2020) 135 (20): 1816.

https://doi.org/10.1182/blood.2020005020

Published: 2020

Journal Articles

Brentuximab vedotin in the treatment of CD30 + PTCL

Stefan K. Barta, Jerald Z. Gong, Pierluigi Porcu

Blood (2019) 134 (26): 2339–2345.

https://doi.org/10.1182/blood.2019001821

Published: 2019

Journal Articles

Subclassifying peripheral T-cell lymphoma NOS

Antonino Carbone, Annunziata Gloghini

Blood (2019) 134 (24): 2120–2121.

https://doi.org/10.1182/blood.2019003385

Published: 2019

Journal Articles

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Blood (2019) 134 (24): 2159–2170.

https://doi.org/10.1182/blood.2019000779

Published: 2019

Includes: Supplemental data

Journal Articles

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Jing-Ping Zhang, PhD, Qi Gao, MLS, Alexander Chan, MD, Wenbin Xiao, MD PhD, Sary El Daker, PhD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 3978.

https://doi.org/10.1182/blood-2019-130406

Published: 2019

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 4050.

https://doi.org/10.1182/blood-2019-127155

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Blood (2019) 134 (Supplement_1): 4036.

https://doi.org/10.1182/blood-2019-129305

Published: 2019

Journal Articles

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Daisuke Kaji, MD, Manabu Kusakabe, MD PhD, Mamiko Sakata-Yanagimoto, MD PhD, Yasuhito Suehara, MD, Keiichiro Hattori, MD PhD, Yasunori Ota, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 4128.

https://doi.org/10.1182/blood-2019-127521

Published: 2019

Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4085.

https://doi.org/10.1182/blood-2019-129347

Published: 2019

Journal Articles

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Lakshman Vasanthamohan, MD FRCPC, Brent Parker, MD, Joy Mangel, MD FRCPC, Selay Lam, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Chai Wye Phua, MD FRCPC

Blood (2019) 134 (Supplement_1): 4131.

https://doi.org/10.1182/blood-2019-126997

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Namrata S Chandhok, MD, Scott F. Huntington, MD MPH, Iris Isufi, MD, Lohith Gowda, MD MRCP, Mina L Xu, MD, Noffar Bar, MD, Stuart Seropian, MD, Francine M. Foss, MD

Blood (2019) 134 (Supplement_1): 4055.

https://doi.org/10.1182/blood-2019-128888

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

The rise of a new “great teacher”

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Outcomes for PTCL: which pathway to success?

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia

Brentuximab vedotin in the treatment of CD30 + PTCL

Subclassifying peripheral T-cell lymphoma NOS

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only